Dosing. Company shall not exceed the maximum allowable dosing levels of Captisol specified in CyDex’s then-current clinical dosing matrix (which shall be provided by CyDex to Company from time to time) without the written consent of CyDex.
Appears in 4 contracts
Samples: License Agreement (Ligand Pharmaceuticals Inc), License Agreement (MEI Pharma, Inc.), License Agreement (Ligand Pharmaceuticals Inc)
Dosing. Company shall not exceed the maximum allowable dosing levels of Captisol specified in CyDex’s then-current clinical dosing matrix (which shall be provided by CyDex to Company from time to timetime or upon Company’s request) without the written consent of CyDex, which consent shall be deemed provided unless CyDex responds in writing objecting thereto within 15 days after CyDex’s receipt of Company’s request to exceed the maximum dosage.
Appears in 2 contracts
Samples: License Agreement (Ligand Pharmaceuticals Inc), License Agreement (Ligand Pharmaceuticals Inc)
Dosing. Company shall not without the written consent of CyDex exceed the maximum allowable dosing levels of Captisol specified in CyDex’s then-current clinical dosing matrix (which shall be provided by CyDex to Company from time to time) without the written consent of CyDex).
Appears in 1 contract
